慢性乙型肝炎及其相关疾病一体化治疗的中西医结合研究

叶永安

doi:10.3969/j.issn.1001-5256.2023.06.001

慢性乙型肝炎及其相关疾病一体化治疗的中西医结合研究

DOI: 10.3969/j.issn.1001-5256.2023.06.001

叶永安^, ,

北京中医药大学中医肝病研究院，北京中医药大学东直门医院，北京 100700

基金项目:

国家科技重大专项“十三五”课题 (2018ZX10725505)

利益冲突声明：本文不存在任何利益冲突。

详细信息

通信作者:
叶永安，yeyongan@vip.163.com (ORCID: 0000-0001-9765-4665)

计量
- 文章访问数: 455
- HTML全文浏览量: 83
- PDF下载量: 106
- 被引次数: 0
出版历程
- 收稿日期: 2023-05-04
- 录用日期: 2023-05-23
- 出版日期: 2023-06-20

An integrated traditional Chinese and Western Medicine study on the comprehensive prevention and treatment of chronic hepatitis B and its related diseases

Yongan YE^{,
,}

Liver Diseases Academy of Traditional Chinese Medicine, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China

Research funding:

National Science and Technology Major Project of China (2018ZX10725505)

More Information

Corresponding author: YE Yongan, yeyongan@vip.163.com (ORCID: 0000-0001-9765-4665)

摘要

摘要: 慢性乙型肝炎及其相关疾病仍是我国乃至全球的重要公共卫生问题和医疗难题，目前尚缺乏有效的根治手段。本文回顾了在“十一五”至“十三五”国家科技重大专项(艾滋病和病毒性肝炎等重大传染病防治专项)支持下，针对乙型肝炎全链条(包括HBV携带者、慢性乙型肝炎、肝纤维化、肝硬化、肝细胞癌癌前病变、肝癌、肝衰竭等不同疾病阶段)形成的中医、中西医结合治疗方案及研究亮点，对中医药在慢性乙型肝炎及其相关疾病一体化治疗中发挥的作用进行了总结与展望。
- 乙型肝炎, 慢性 /
- 中西医结合疗法 /
- 治疗学
Abstract: Chronic hepatitis B and its related diseases remain important public health problems and tough medical issues in China and even around the world, and now there is still a lack of effective radical treatment methods. This article reviews the traditional Chinese Medicine treatment regimens, the integrated traditional Chinese and Western Medicine treatment regimens, and related research highlights formed for hepatitis B (including various disease stages such as HBV carriers, chronic hepatitis B, liver fibrosis, liver cirrhosis, precancerous lesions of hepatocellular carcinoma, liver cancer, and liver failure) under the support of National Science and Technology Major Project from "The 11th Five-Year Plan" to "The 13th Five-Year Plan" (Prevention and Treatment of Major Infectious Diseases such as AIDS and Viral Hepatitis), and it also summarizes the role of traditional Chinese Medicine in the comprehensive prevention and treatment of chronic hepatitis B and its related diseases.
- Hepatitis B, Chronic /
- Integrated Chinese Traditional and Western Medicine Therapy /
- Therapeutics

HTML全文

参考文献(86)

[1]	Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3(6): 383-403. DOI: 10.1016/S2468-1253(18)30056-6.
[2]	SORIANO V, ALVAREZ C, EDAGWA B, et al. Ultra-long-acting (XLA) antivirals for chronic viral hepatitis[J]. Int J Infect Dis, 2022, 114: 45-50. DOI: 10.1016/j.ijid.2021.10.052.
[3]	EASTERBROOK P, LUHMANN N, NEWMAN M, et al. New WHO guidance for country validation of viral hepatitis B and C elimination[J]. Lancet Gastroenterol Hepatol, 2021, 6(10): 778-780. DOI: 10.1016/S2468-1253(21)00267-3.
[4]	Chinese Society of Hepatology, Chinese Medical Association. Expand expert advice on antiviral therapy for chronic hepatitis B[J]. Chin J Hepatol, 2022, 30(2): 131-136. DOI: 10.3760/cma.j.cn501113-20220209-00060. 中华医学会肝病学分会. 扩大慢性乙型肝炎抗病毒治疗的专家意见[J]. 中华肝脏病杂志, 2022, 30(2): 131-136. DOI: 10.3760/cma.j.cn501113-20220209-00060.
[5]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2022)[J]. Infect Dis Info, 2023, 36(1): 1-17. DOI: 10.3969/j.issn.1007-8134.2023.01.01. 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 传染病信息, 2023, 36(1): 1-17. DOI: 10.3969/j.issn.1007-8134.2023.01.01.
[6]	KIM GA, LIM YS, HAN S, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B[J]. Gut, 2018, 67(5): 945-952. DOI: 10.1136/gutjnl-2017-314904.
[7]	KIM JH, SINN DH, KANG W, et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment[J]. Hepatology, 2017, 66(2): 335-343. DOI: 10.1002/hep.28916.
[8]	American Gastroenterological Association. AGA Section. AGA hepatitis B virus reactivation guideline: patient summary[J]. Gastroenterology, 2015, 149(2): 496-497. DOI: 10.1053/j.gastro.2015.06.041.
[9]	Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B: a 2015 update[J]. J Clin Hepatol, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002. 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版)[J]. 临床肝胆病杂志, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002.
[10]	CHEN EQ, WANG ML, TAO YC, et al. Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA[J]. J Viral Hepat, 2019, 26(5): 586-595. DOI: 10.1111/jvh.13061.
[11]	TESTONI B, LEBOSSÉ F, SCHOLTES C, et al. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients[J]. J Hepatol, 2019, 70(4): 615-625. DOI: 10.1016/j.jhep.2018.11.030.
[12]	CHANG Y, CHOE WH, SINN DH, et al. Nucleos(t)ide analogue treatment for patients with hepatitis B virus (HBV) e antigen-positive chronic HBV genotype C infection: A nationwide, multicenter, retrospective study[J]. J Infect Dis, 2017, 216(11): 1407-1414. DOI: 10.1093/infdis/jix506.
[13]	CAREY I, D'ANTIGA L, BANSAL S, et al. Immune and viral profile from tolerance to hepatitis B surface antigen clearance: a longitudinal study of vertically hepatitis B virus-infected children on combined therapy[J]. J Virol, 2011, 85(5): 2416-2428. DOI: 10.1128/JVI.01449-10.
[14]	D'ANTIGA L, AW M, ATKINS M, et al. Combined lamivudine/interferon-alpha treatment in "immunotolerant" children perinatally infected with hepatitis B: a pilot study[J]. J Pediatr, 2006, 148(2): 228-233. DOI: 10.1016/j.jpeds.2005.09.020.
[15]	XIAO Y, ZENG Y, ALEXANDER E, et al. Adsorption of recombinant poxvirus L1-protein to aluminum hydroxide/CpG vaccine adjuvants enhances immune responses and protection of mice from vaccinia virus challenge[J]. Vaccine, 2013, 31(2): 319-326. DOI: 10.1016/j.vaccine.2012.11.007.
[16]	Branch of Hepatobiliary Diseases, Chinese Association of Chinese Medicine. The standards of traditional Chinese medicine syndrome differentiation for viral hepatitis[J]. J Clin Hepatol, 2017, 33(10): 1839-1846. DOI: 10.3969/j.issn.1001-5256.2017.10.002. 中华中医药学会肝胆病分会. 病毒性肝炎中医辨证标准[J]. 临床肝胆病杂志, 2017, 33(10): 1839-1846. DOI: 10.3969/j.issn.1001-5256.2017.10.002.
[17]	XING YF, ZHANG XH, CHEN YJ, et al. Pathogenesis discussion and TCM syndrome distribution law of chronic hepatitis B virus carriers[J]. Chin J Integr Tradit West Med Liver Dis, 2012, 22(4): 196-199. DOI: 10.3969/j.issn.1005-0264.2012.04.002. 邢宇锋, 张晓晖, 陈英杰, 等. 慢性乙肝病毒携带者中医证候分布规律调查及病机探讨[J]. 中西医结合肝病杂志, 2012, 22(4): 196-199. DOI: 10.3969/j.issn.1005-0264.2012.04.002.
[18]	CHEN YJ, LI HZ, TONG GD, et al. Antiviral therapeutic effects of bushen qingtou prescription to hepatitis B virus carriers with positive e antigen[J]. Chin J Exp Med Formul, 2013, 19(7): 283-288. DOI: 10.11653/zgsyfjxzz2013070283. 陈英杰, 李慧贞, 童光东, 等. 补肾清透方对e-抗原阳性乙肝病毒携带者的抗病毒疗效[J]. 中国实验方剂学杂志, 2013, 19(7): 283-288. DOI: 10.11653/zgsyfjxzz2013070283.
[19]	CHEN YJ, ZHOU DQ, TONG GD, et al. Immunemodulatory effect of Bushen Jianpi recipe on HBeAg-positive hepatitis B virus carriers[J]. Clin J Chin Med, 2013, 5(12): 1-5. DOI: 10.3969/j.issn.1674-7860.2013.12.001. 陈英杰, 周大桥, 童光东, 等. 补肾健脾方对HBeAg阳性乙肝病毒携带者的免疫调节作用[J]. 中医临床研究, 2013, 5(12): 1-5. DOI: 10.3969/j.issn.1674-7860.2013.12.001.
[20]	XING YF, TONG GD, ZHOU DQ, et al. Effect of tonifying kidney therapy on pathology of chronic hepatitis B virus carriers[J]. Chin J Inf Tradit Chin Med, 2016, 23(5): 24-27. DOI: 10.3969/j.issn.1005-5304.2016.05.007. 邢宇锋, 童光东, 周大桥, 等. 补肾法对慢性乙型肝炎病毒携带者肝组织病理的影响[J]. 中国中医药信息杂志, 2016, 23(5): 24-27. DOI: 10.3969/j.issn.1005-5304.2016.05.007.
[21]	XING YF, XU L Y, FENG J, et al. A multicenter, randomized, double-blind clinical trial on a Chinese Herbal Formula (Bushen Jianpi Jiedu Prescription) in the Treatment of Chronic Hepatitis B Virus Carriers[J]. Chin J Integr Tradit West Med Liver Dis, 2021, 31(7): 586-589, 605. DOI: 10.3969/j.issn.1005-0264.2021.07.003. 邢宇锋, 许林艺, 冯楝, 等. 补肾健脾解毒方治疗慢性乙型肝炎病毒携带者的临床研究[J]. 中西医结合肝病杂志, 2021, 31(7): 586-589, 605. DOI: 10.3969/j.issn.1005-0264.2021.07.003.
[22]	Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[23]	DUSHEIKO G, AGARWAL K, MAINI MK. New approaches to chronic hepatitis B. reply[J]. N Engl J Med, 2023, 388(12): 1148-1149. DOI: 10.1056/NEJMc2301248.
[24]	SONNEVELD MJ, CHIU SM, PARK JY, et al. Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels[J]. J Hepatol, 2022, 76(5): 1042-1050. DOI: 10.1016/j.jhep.2022.01.007.
[25]	GAO YQ, WANG LT. Discussion and study on Chinese medicine syndrome types of chronic hepatitis B[J]. Chin J Basic Med Tradit Chin Med, 2003(8): 40-41. DOI: 10.3969/j.issn.1006-3250.2003.08.016. 高月求, 王灵台. 慢性乙型肝炎中医证型研究探讨[J]. 中国中医基础医学杂志, 2003(8): 40-41. DOI: 10.3969/j.issn.1006-3250.2003.08.016.
[26]	ZHU XJ, SUN XH, ZHOU ZH, et al. Lingmao formula combined with entecavir for hbeag-positive chronic hepatitis B patients with mildly elevated alanine aminotransferase: a multicenter, randomized, double-blind, placebo-controlled trial[J]. Evid Based Complement Alternat Med, 2013, 2013: 620230. DOI: 10.1155/2013/620230.
[27]	ZHANG JH, ZHANG X, ZHOU ZH, et al. Bushen jianpi formula combined with entecavir for the treatment of hbeag-negative chronic hepatitis B: a multicenter, randomized, double-blind, placebo-controlled trial[J]. Evid Based Complement Alternat Med, 2022, 2022: 6097221. DOI: 10.1155/2022/6097221.
[28]	JI LS, GAO QT, GUO RW, et al. Immunomodulatory effects of combination therapy with bushen formula plus entecavir for chronic hepatitis B patients[J]. J Immunol Res, 2019, 2019: 8983903. DOI: 10.1155/2019/8983903.
[29]	LI M, ZHOU ZH, BAO T, et al. Beneficial effects of bushen formula combined with enticavir on chronic hepatitis B patients with suboptimal response to enticavir by regulating B-cell differentiation[J]. Cell Physiol Biochem, 2018, 48(2): 633-643. DOI: 10.1159/000491891.
[30]	LI M, SUN XH, ZHOU ZH, et al. Beneficial therapeutic effect of Chinese herbal Bushen formula on CHB patients with mildly elevated alanine aminotransferase by down-regulating CD4⁺CD25⁺T cells[J]. J Ethnopharmacol, 2013, 146(2): 614-622. DOI: 10.1016/j.jep.2013.01.038.
[31]	YE YA, JIANG F, ZHAO ZM, et al. Chinese medical pattern distribution of chronic type hepatitis B[J]. J Tradit Chin Med, 2007(3): 256-258. DOI: 10.3321/j.issn:1001-1668.2007.03.034. 叶永安, 江锋, 赵志敏, 等. 慢性乙型肝炎中医证型分布规律研究[J]. 中医杂志, 2007(3): 256-258. DOI: 10.3321/j.issn:1001-1668.2007.03.034.
[32]	YE YA, TIAN DL, JIANG J, et al. Study on common symptoms and distribution characteristics of traditional chinese medicine syndromes of 1 003 chronic hepatitis B (ALT≥2ULN) patients[J]. World Chin Med, 2015, 10(9): 1293-1298, 1304. DOI: 10.3969/j.issn.1673-7202.2015.09.001. 叶永安, 田德禄, 蒋健, 等. 1003例慢性乙型肝炎(ALT≥2×ULN)患者中医常见症状及证候分布特点研究[J]. 世界中医药, 2015, 10(9): 1293-1298, 1304. DOI: 10.3969/j.issn.1673-7202.2015.09.001.
[33]	YE YA, LI XK, ZHOU DQ, et al. Chinese herbal medicine combined with entecavir for hbeag positive chronic hepatitis B: study protocol for a multi-center, double-blind randomized-controlled trial[J]. Chin J Integr Med, 2018, 24(9): 653-660. DOI: 10.1007/s11655-018-3011-5.
[34]	LI XK, ZHANG MX, SHAO FZ, et al. Adefovir dipivoxil plus chinese medicine in hbeag-positive chronic hepatitis B patients: a randomized controlled 48-week trial[J]. Chin J Integr Med, 2020, 26(5): 330-338. DOI: 10.1007/s11655-020-3250-0.
[35]	LI X, ZHOU D, CHI X, et al. Entecavir combining Chinese herbal medicine for HBeAg-positive chronic hepatitis B patients: a randomized, controlled trial[J]. Hepatol Int, 2020, 14(6): 985-996. DOI: 10.1007/s12072-020-10097-z.
[36]	LI X, ZHANG L, QIU M, et al. Chinese herbal medicine combined with entecavir to reduce the off-therapy recurrence risk in HBeAg-positive chronic hepatitis B patients: a multicener, double-blind, randomized controlled trial in China[J]. Trials, 2020, 21(1): 708. DOI: 10.1186/s13063-020-04417-9.
[37]	LI XK, MEI Q, YI H, et al. Consolidation treatment with Tiaogan-Buxu-Jiedu granule (Traditional Chinese Medicine compound) plus entecavir reduces virological relapse following entecavir withdrawal in Chinese patients with chronic hepatitis B: a randomized, controlled trial[C]. Annual Meeting of the European Association for the Study of the Liver. Vienna, 2023.
[38]	LI XK, MEI Q, YI H, et al. Utilizing machine learning-based predictive models to identify early virological recurrence in Chinese chronic hepatitis B patients following entecavir withdrawal[C]. Annual Meeting of the European Association for the Study of the Liver. Vienna, 2023.
[39]	WU T, LI J, SHAO L, et al. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure[J]. Gut, 2018, 67(12): 2181-2191. DOI: 10.1136/gutjnl-2017-314641.
[40]	SETO WK, LAI CL, YUEN MF. Acute-on-chronic liver failure in chronic hepatitis B[J]. J Gastroenterol Hepatol, 2012, 27(4): 662-669. DOI: 10.1111/j.1440-1746.2011.06971.x.
[41]	HU JH, WANG HF, HE WP, et al. Lamivudine and entecavir significantly improved the prognosis of early-to-mid stage hepatitis B related acute on chronic liver failure[J]. Chin J Exp Clin Virol, 2010, 24(3): 205-208. DOI: 10.3760/cma.j.issn.1003-9279.2010.03.015. 胡瑾华, 王慧芬, 何卫平, 等. 核苷类似物治疗早中期HBV-ACLF患者随机对照临床研究[J]. 中华实验和临床病毒学杂志, 2010, 24(3): 205-208. DOI: 10.3760/cma.j.issn.1003-9279.2010.03.015.
[42]	CUI YL, YAN F, WANG YB, et al. Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection-associated acute on chronic liver failure[J]. Dig Dis Sci, 2010, 55(8): 2373-2380. DOI: 10.1007/s10620-010-1257-7.
[43]	LI J. Clinical research progress in integrated traditional Chinese and Western medicine therapy for HBV-related liver failure[J]. J Clin Hepatol, 2015, 31(1): 42-47. DOI: 10.3969/j.issn.1001-5256.2015.01.010. 李筠. 乙型肝炎肝衰竭的中西医结合治疗策略[J]. 临床肝胆病杂志, 2015, 31(1): 42-47. DOI: 10.3969/j.issn.1001-5256.2015.01.010.
[44]	WANG M, GONG M, TANG JM, et al. Experience of LI Jun in treating acute-on-chronic liver failure with Chinese traditional therapy[J]. China J Tradit Chin Med Pharma, 2018, 33(6): 2419-2421. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201806052.htm 王敏, 宫嫚, 唐金模, 等. 李筠中医治疗慢加急性肝衰竭经验[J]. 中华中医药杂志, 2018, 33(6): 2419-2421. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201806052.htm
[45]	ZHOU C, GONG M, ZHANG N, et al. Study on the intervention of integrated traditional Chinese and Western medicine therapy in patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Chin J Integr Tradit West Med Liver Dis, 2019, 29(3): 203-207. DOI: 10.3969/j.issn.1005-0264.2019.03.004. 周超, 宫嫚, 张宁, 等. 中西医结合治疗方案干预乙型肝炎病毒相关慢加急性肝衰竭的疗效分析[J]. 中西医结合肝病杂志, 2019, 29(3): 203-207. DOI: 10.3969/j.issn.1005-0264.2019.03.004.
[46]	BATALLER R, BRENNER DA. Liver fibrosis[J]. J Clin Invest, 2005, 115(2): 209-218. DOI: 10.1172/JCI24282.
[47]	Liver Disease Committee, Chinese Association of Integrative Medicine. Guidelines for the diagnosis and treatment of liver fibrosis in integrative medicine practice (2019)[J]. J Clin Hepatol, 2019, 35(7): 1444-1449. DOI: 10.3969/j.issn.1001-5256.2019.07.007. 中国中西医结合学会肝病专业委员会. 肝纤维化中西医结合诊疗指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(7): 1444-1449. DOI: 10.3969/j.issn.1001-5256.2019.07.007.
[48]	BAI YM, LIANG S, ZHOU B. Research Progress of Combined Treatment of Liver Fibrosis with Traditional Chinese and Western Medicine[J]. J Pract Tradit Chin Int Med, 2022. [Online ahead of print] 白彦铭, 梁爽, 周波. 中西医联合治疗肝纤维化的研究进展[J]. 实用中医内科杂志, 2022. [网络首发]
[49]	LEE YA, WALLACE MC, FRIEDMAN SL. Pathobiology of liver fibrosis: a translational success story[J]. Gut, 2015, 64(5): 830-841. DOI: 10.1136/gutjnl-2014-306842.
[50]	MARCELLIN P, GANE E, BUTI M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study[J]. Lancet, 2013, 381(9865): 468-475. DOI: 10.1016/S0140-6736(12)61425-1.
[51]	CHANG TT, LIAW YF, WU SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B[J]. Hepatology, 2010, 52(3): 886-893. DOI: 10.1002/hep.23785.
[52]	OZE T, HIRAMATSU N, YAKUSHIJIN T, et al. Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy[J]. Clin Gastroenterol Hepatol, 2014, 12(7): 1186-1195. DOI: 10.1016/j.cgh.2013.11.033.
[53]	XIAO HM, SHI MJ, JIANG JM, et al. Efficacy and safety of AnluoHuaxian pills on chronic hepatitis B with normal or minimally elevated alanine transaminase and early liver fibrosis: A randomized controlled trial[J]. J Ethnopharmacol, 2022, 293: 115210. DOI: 10.1016/j.jep.2022.115210.
[54]	MIAO L, YANG WN, DONG XQ, et al. Combined anluohuaxianwan and entecavir treatment significantly improve the improvement rate of liver fibrosis in patients with chronic hepatitis B virus infection[J]. Chin J Hepatol, 2019, 27(7): 521-526. DOI: 10.3760/cma.j.issn.1007-3418.2019.07.009. 苗亮, 杨婉娜, 董晓琴, 等. 安络化纤丸联合恩替卡韦治疗可显著提高慢性乙型肝炎病毒感染者肝纤维化的改善率[J]. 中华肝脏病杂志, 2019, 27(7): 521-526. DOI: 10.3760/cma.j.issn.1007-3418.2019.07.009.
[55]	SHI MJ, XIAO HM, XIE YB, et al. Whether chronic viral hepatitis B should be treated in immunotolerant patients: stratified results of a randomized controlled clinical trial[J]. Pharmocol Clin Chin Mater Med, 2023, 39(1): 62-66. DOI: 10.13412/j.cnki.zyyl.20220614.001. 施梅姐, 萧焕明, 谢玉宝, 等. 慢性乙型病毒性肝炎免疫耐受期患者应否治疗: 一项临床随机对照试验的分层分析结果[J]. 中药药理与临床, 2023, 39(1): 62-66. DOI: 10.13412/j.cnki.zyyl.20220614.001.
[56]	ZHUO YX, PENG MN, LIN M, et al. Evaluation of clinical effect of therapy of soothing liver and invigorating spleen for treatment of hepatitis B associated hepatic fibrosis[J]. J Guangzhou Univ Tradit Chin Med, 2020, 37(11): 2063-2068. DOI: 10.13359/j.cnki.gzxbtcm.2020.11.003. 卓永祥, 彭梦楠, 林明, 等. 运用疏肝健脾法治疗乙肝肝纤维化的临床疗效评价[J]. 广州中医药大学学报, 2020, 37(11): 2063-2068. DOI: 10.13359/j.cnki.gzxbtcm.2020.11.003.
[57]	RONG G, CHEN Y, YU Z, et al. Synergistic effect of biejia-ruangan on fibrosis regression in patients with chronic hepatitis B treated with entecavir: a multicenter, randomized, double-blind, placebo-controlled trial[J]. J Infect Dis, 2022, 225(6): 1091-1099. DOI: 10.1093/infdis/jiaa266.
[58]	JI D, CHEN Y, BI J, et al. Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B[J]. J Hepatol, 2022, 77(6): 1515-1524. DOI: 10.1016/j.jhep.2022.07.018.
[59]	TERRAULT NA, BZOWEJ NH, CHANG KM, et al. AASLD guidelines for treatment of chronic hepatitis B[J]. Hepatology, 2016, 63(1): 261-283. DOI: 10.1002/hep.28156.
[60]	LOK AS, MCMAHON BJ, BROWN RS Jr, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis[J]. Hepatology, 2016, 63(1): 284-306. DOI: 10.1002/hep.28280.
[61]	PAPATHEODORIDIS GV, IDILMAN R, DALEKOS GN, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B[J]. Hepatology, 2017, 66(5): 1444-1453. DOI: 10.1002/hep.29320.
[62]	POYNARD T, MASSARD J, RUDLER M, et al. Impact of interferon-alpha treatment on liver fibrosis in patients with chronic hepatitis B: an overview of published trials[J]. Gastroenterol Clin Biol, 2009, 33(10-11): 916-922. DOI: 10.1016/j.gcb.2009.06.006.
[63]	TAN PS, AUNG MO, DAN YY, et al. Liver disease progression and virological response: entecavir rescue still possible in the setting of rtM204I lamivudine-resistant mutation[J]. Gut, 2013, 62(5): 801-802. DOI: 10.1136/gutjnl-2012-303647.
[64]	RAMACHANDRAN P, HENDERSON NC. Antifibrotics in chronic liver disease: tractable targets and translational challenges[J]. Lancet Gastroenterol Hepatol, 2016, 1(4): 328-340. DOI: 10.1016/S2468-1253(16)30110-8.
[65]	PAWLOTSKY JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens[J]. Gastroenterology, 2016, 151(1): 70-86. DOI: 10.1053/j.gastro.2016.04.003.
[66]	REIG M, MARIÑO Z, PERELLÓ C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy[J]. J Hepatol, 2016, 65(4): 719-726. DOI: 10.1016/j.jhep.2016.04.008.
[67]	ZHAO ZM, ZHU CW, HUANG JQ, et al. Efficacy and safety of Fuzheng Huayu tablet on persistent advanced liver fibrosis following 2 years entecavir treatment: A single arm clinical objective performance criteria trial[J]. J Ethnopharmacol, 2022, 298: 115599. DOI: 10.1016/j.jep.2022.115599.
[68]	LI ZX, ZHAO ZM, LIU P, et al. Treatment of HBV Cirrhosis with Fuzheng Huayu Tablet and entecavir: design of a randomized, double-blind, parallel and multicenter clinical trial[J]. Chin J Integr Med, 2021, 27(7): 509-513. DOI: 10.1007/s11655-020-3257-6.
[69]	SHI K, LIU Y, WANG X, et al. Adjuvant Fuzheng Huayu Capsule reduces the incidence of hepatocellular carcinoma in patients with hepatitis B-caused cirrhosis[J]. Evid Based Complement Alternat Med, 2020, 2020: 8826091. DOI: 10.1155/2020/8826091.
[70]	XIAO DH, GU J, CAI H, et al. A randomized placebo-controlled multicentre study of Fuzhenghuayu capsule for prevention of oesophageal variceal bleeding in patients with liver cirrhosis[J]. Chin J Hepatol, 2014, 22(8): 594-599. DOI: 10.3760/cma.j.issn.1007-3418.2014.08.009. 肖定洪, 顾杰, 蔡虹, 等. 扶正化瘀胶囊预防肝硬化患者食管静脉曲张破裂出血的随机对照多中心临床研究[J]. 中华肝脏病杂志, 2014, 22(8): 594-599. DOI: 10.3760/cma.j.issn.1007-3418.2014.08.009.
[71]	LI Y, YE YA, LI ZG, et al. Study on the Mechanism of Kangxianyiai formula delay the occurrence of hepatic precancerous lesions by regulating the signal pathway of PI3K-Akt[J]. Chin J Integr Tradit West Med Liver Dis, 2019, 29(3): 240-243, 289. DOI: 10.3969/j.issn.1005-0264.2019.03.014. 李莹, 叶永安, 李志国, 等. 基于PI3K/Akt信号通路探讨抗纤抑癌方干预肝癌前病变的作用机制[J]. 中西医结合肝病杂志, 2019, 29(3): 240-243, 289. DOI: 10.3969/j.issn.1005-0264.2019.03.014.
[72]	LI Y, YE YA, ZHANG LD, et al. Effects of Kangxian Yi'ai Formula on integrin α5β1/FAK signaling pathway in rats with hepatic precancerous lesions[J]. China J Tradit Chin Med Pharma, 2019, 34(2): 759-762. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201902090.htm 李莹, 叶永安, 张露丹, 等. 抗纤抑癌方对肝癌前病变大鼠整合素α5β1/FAK信号通路的影响[J]. 中华中医药杂志, 2019, 34(2): 759-762. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201902090.htm
[73]	LIU RJ, YANG XZ, ZHANG P, et al. Efficacy observation on Kangxian Yi ai formula in rats with liver precancerous lesions[J]. World Chin Med, 2015, 10(9): 1309-1312. DOI: 10.3969/j.issn.1673-7202.2015.09.004. 刘蕊洁, 杨先照, 张鹏, 等. 抗纤抑癌方干预大鼠肝癌前病变疗效观察[J]. 世界中医药, 2015, 10(9): 1309-1312. DOI: 10.3969/j.issn.1673-7202.2015.09.004.
[74]	YANG XZ, LIU RJ, JIAO YT, et al. Regulation effects of kangxian yiai formula on Ras/Erk signal pathway in the rats with hepatic precancerous lesions[J]. World J Integr Tradit Western Med, 2018, 13(10): 1340-1343. DOI: 10.13935/j.cnki.sjzx.181003. 杨先照, 刘蕊洁, 焦云涛, 等. 抗纤抑癌方对肝癌前病变大鼠Ras/Erk信号通路的调控作用研究[J]. 世界中西医结合杂志, 2018, 13(10): 1340-1343. DOI: 10.13935/j.cnki.sjzx.181003.
[75]	YE YA, YANG XZ, JIANG F. Experimental study on the effect of Kangxian Yiai Fang on hepatocyte growth factor and its receptor in precancerous lesion of liver[C]. The 15th Academic Conference of Internal Medicine and Hepatobiliary Diseases of the Chinese Association of Traditional Chinese Medicine and the Meeting of the Special Disease Collaboration Group (Hepatology Group, Infectious Disease Group) of the State Administration of Traditional Chinese Medicine. Jinan, 2012. 叶永安, 杨先照, 江锋. 抗纤抑癌方对肝癌前病变肝细胞生长因子及其受体的影响实验研究[C]. 中华中医药学会第十五届内科肝胆病学术会议暨国家中医药管理局专科专病协作组(肝病组、传染病组)会议. 济南, 2012.
[76]	FENG LL, ZHANG J, MAO WC, et al. Pharmacokinetics of baicalin in hepatic precancerous mice induced by diethylnitrosamine[J]. China J Tradit Chin Med Pharma, 2013, 28(10): 3063-3067. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201310069.htm 冯丽莉, 张健, 毛文超, 等. 黄芩苷在二乙基亚硝胺诱发肝癌前病变小鼠体内药动学考察[J]. 中华中医药杂志, 2013, 28(10): 3063-3067. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201310069.htm
[77]	JIAO YB, LIU XT, MAO WC, et al. Preventive effect of curcumin on DEN-induced hepatic precancerous lesions in mice[J]. China Pharmacist, 2012, 15(9): 1218-1222. DOI: 10.3969/j.issn.1008-049X.2012.09.002. 焦艺博, 刘晓婷, 毛文超, 等. 姜黄素对二乙胺基亚硝胺诱发小鼠肝癌前病变的预防作用[J]. 中国药师, 2012, 15(9): 1218-1222. DOI: 10.3969/j.issn.1008-049X.2012.09.002.
[78]	SONG YJ, YANG SJ, WANG X, et al. Study on pharmacokinetics of Paeonol(Pae) in hepatic precancerous lesion model in rats[J]. Chin J Integr Tradit West Med Liver Dis, 2018, 28(1): 37-40, 67. DOI: 10.3969/j.issn.1005-0264.2018.01.013. 宋艺君, 杨史军, 王湘, 等. 丹皮酚在肝癌前病变大鼠体内的药动学研究[J]. 中西医结合肝病杂志, 2018, 28(1): 37-40, 67. DOI: 10.3969/j.issn.1005-0264.2018.01.013.
[79]	ZHOU M, WANG H, ZENG X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145-1158. DOI: 10.1016/S0140-6736(19)30427-1.
[80]	CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-32. DOI: 10.3322/caac.21338
[81]	XIA Y, LI J, LIU G, et al. Long-term effects of repeat hepatectomy vs percutaneous radiofrequency ablation among patients with recurrent hepatocellular carcinoma: a randomized clinical trial[J]. JAMA Oncol, 2020, 6(2): 255-263. DOI: 10.1001/jamaoncol.2019.4477.
[82]	HUANG G, LAI EC, LAU WY, et al. Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels[J]. Ann Surg, 2013, 257(3): 490-505. DOI: 10.1097/SLA.0b013e318262b218.
[83]	XUE D, ZHANG XT, KUANG YH, et al. The clinical efficacy of FuzhengXiaoliu granule in the treatment of stage Ⅲa primary liver cancer after comprehensive intervention and its effect on serum FGFR4 and TGF-β1[J]. Chin J Integr Tradit West Med Liver Dis, 2022, 32(5): 406-409. DOI: 10.3969/j.issn.1005-0264.2022.05.005. 薛丹, 张笑天, 邝玉慧, 等. 扶正消瘤颗粒治疗综合介入术后Ⅲa期原发性肝癌患者临床疗效及对血清FGFR4、TGF-β1的影响[J]. 中西医结合肝病杂志, 2022, 32(5): 406-409. DOI: 10.3969/j.issn.1005-0264.2022.05.005.
[84]	National Science and Technology Major Project of the Ministry of Science and Technology of China-Prevention and Treatment of Major Infectious Diseases such as AIDS and Viral Hepatitis-Research Group of "Comprehensive Treatment Plan for Retarding Hepatitis B Related Liver Cancer Progression with Traditional Chinese Medicine", Oncology Expert Committee of Integrated Traditional Chinese and Western Medicine Branch of Chinese Medical Doctor Association, Digestive Rehabilitation Branch of Henan Rehabilitation Medical Association, et al. Expert consensus on integrated traditional Chinese and Western medicine rehabilitation after transcatheter arterial chemoembolization for primary liver cancer[J]. J Clin Hepatol, 2021, 37(7): 1545-1549. DOI: 10.3969/j.issn.1001-5256.2021.07.013. 国家艾滋病和病毒性肝炎等重大传染病防治科技专项"中医药延缓乙型肝炎相关肝癌进展的综合治疗方案研究"课题组, 中国医师协会中西医结合分会肿瘤专业委员会, 河南省康复医学会消化康复分会, 等. 原发性肝癌经肝动脉化疗栓塞术后中西医结合康复专家共识[J]. 临床肝胆病杂志, 2021, 37(7): 1545-1549. DOI: 10.3969/j.issn.1001-5256.2021.07.013.
[85]	YU X, LIN XJ, WANG S, et al. Antitumor efficacy of Huqizhengxiao (HQZX) decoction based on inhibition of telomerase activity in nude mice of hepatocarcinoma xenograft[J]. Integr Cancer Ther, 2018, 17(4): 1216-1224. DOI: 10.1177/1534735418785999.
[86]	YANG KR, YE YA. Ye Yongan's experience in treating liver cancer[J]. Chin J Basic Med Tradit Chin Med, 2013, 19(10): 1145. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJC201310016.htm 杨昆蓉, 叶永安. 叶永安治疗肝癌经验[J]. 中国中医基础医学杂志, 2013, 19(10): 1145. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJC201310016.htm